Literature DB >> 27281742

Approved Antiviral Drugs over the Past 50 Years.

Erik De Clercq1, Guangdi Li2.   

Abstract

Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox). Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27281742      PMCID: PMC4978613          DOI: 10.1128/CMR.00102-15

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  472 in total

1.  A history of influenza.

Authors:  C W Potter
Journal:  J Appl Microbiol       Date:  2001-10       Impact factor: 3.772

2.  Antiviral, immunosuppressive and antitumour effects of ribavirin.

Authors:  C W Potter; J P Phair; L Vodinelich; R Fenton; R Jennings
Journal:  Nature       Date:  1976-02-12       Impact factor: 49.962

3.  Evidence gathered from randomized clinical trials and observational studies on the equivalence of emtricitabine and Lamivudine.

Authors:  Casper Rokx; Bart J A Rijnders
Journal:  Clin Infect Dis       Date:  2015-02-16       Impact factor: 9.079

Review 4.  Update on new antivirals under development for the treatment of double-stranded DNA virus infections.

Authors:  L K Dropulic; J I Cohen
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

5.  Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.

Authors:  Astrid-Jane Greenup; Pok Kern Tan; Vi Nguyen; Anne Glass; Scott Davison; Ushmi Chatterjee; Susan Holdaway; Dev Samarasinghe; Kathy Jackson; Stephen A Locarnini; Miriam T Levy
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

6.  Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.

Authors:  Daria J Hazuda; Steven D Young; James P Guare; Neville J Anthony; Robert P Gomez; John S Wai; Joseph P Vacca; Larry Handt; Sherri L Motzel; Hilton J Klein; Geethanjali Dornadula; Robert M Danovich; Marc V Witmer; Keith A A Wilson; Lynda Tussey; William A Schleif; Lori S Gabryelski; Lixia Jin; Michael D Miller; Danilo R Casimiro; Emilio A Emini; John W Shiver
Journal:  Science       Date:  2004-07-08       Impact factor: 47.728

7.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

8.  Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.

Authors:  Thomas Goldner; Christine Hempel; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 9.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

Review 10.  Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.

Authors:  Lindsay Broadbent; Helen Groves; Michael D Shields; Ultan F Power
Journal:  Influenza Other Respir Viruses       Date:  2015-07       Impact factor: 4.380

View more
  335 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

2.  No longer 'written off' - times have changed for the BBV-infected dental professional.

Authors:  J Bagg; K Roy; L Hopps; I Black; D Croser; C O'Halloran; F Ncube
Journal:  Br Dent J       Date:  2017-01-13       Impact factor: 1.626

3.  A chronicle of SARS-CoV-2: Seasonality, environmental fate, transport, inactivation, and antiviral drug resistance.

Authors:  Manish Kumar; Payal Mazumder; Sanjeeb Mohapatra; Alok Kumar Thakur; Kiran Dhangar; Kaling Taki; Santanu Mukherjee; Arbind Kumar Patel; Prosun Bhattacharya; Pranab Mohapatra; Jörg Rinklebe; Masaaki Kitajima; Faisal I Hai; Anwar Khursheed; Hiroaki Furumai; Christian Sonne; Keisuke Kuroda
Journal:  J Hazard Mater       Date:  2020-10-06       Impact factor: 10.588

4.  Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway.

Authors:  Ellen M Bouma; Denise P I van de Pol; Ilson D Sanders; Izabela A Rodenhuis-Zybert; Jolanda M Smit
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

5.  Enterovirus D68 Antivirals: Past, Present, and Future.

Authors:  Yanmei Hu; Rami Musharrafieh; Madeleine Zheng; Jun Wang
Journal:  ACS Infect Dis       Date:  2020-05-14       Impact factor: 5.084

6.  NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2.

Authors:  Yuwen Qin; Binbin Xue; Chunyan Liu; Xiaohong Wang; Renyun Tian; Qinya Xie; Mengmeng Guo; Guangdi Li; Darong Yang; Haizhen Zhu
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

7.  Development of vaccines and antivirals for combating viral pandemics.

Authors:  Norbert Pardi; Drew Weissman
Journal:  Nat Biomed Eng       Date:  2020-12       Impact factor: 25.671

Review 8.  Phytotoxicity and Other Adverse Effects on the In Vitro Shoot Cultures Caused by Virus Elimination Treatments: Reasons and Solutions.

Authors:  Katalin Magyar-Tábori; Nóra Mendler-Drienyovszki; Alexandra Hanász; László Zsombik; Judit Dobránszki
Journal:  Plants (Basel)       Date:  2021-03-31

9.  Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.

Authors:  Shuo Wu; Qiong Zhao; Pinghu Zhang; John Kulp; Lydia Hu; Nicky Hwang; Jiming Zhang; Timothy M Block; Xiaodong Xu; Yanming Du; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

10.  ANERGY TO SYNERGY-THE ENERGY FUELING THE RXCOVEA FRAMEWORK.

Authors:  Evelyne Bischof; Jantine A C Broek; Charles R Cantor; Ashley J Duits; Alfredo Ferro; Hillary W Gao; Zilong Li; Stella Luna de Maria; Naomi I Maria; Bud Mishra; Kimberly I Mishra; Lex van der Ploeg; Larry Rudolph; Tamar Schlick
Journal:  Int J Multiscale Comput Eng       Date:  2020       Impact factor: 1.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.